[Prevention of infections of the respiratory tract in children with RU 41740].
Several double-blind drug versus placebo trials have been carried out to evaluate the effectiveness of RU 41740 in the treatment of recurrent respiratory infections in children. The compound was administered in doses of two tablets per day for one week during the first month and one tablet per day for one week during the second and third months. Effectiveness was assessed 1, 3 and 6 months after the end of the treatment period. These trials have shown that RU 41740 is well tolerated both clinically and biochemically and that it decreases the number, duration and complications of respiratory infections, as well as the consumption of antibiotics during the infectious episodes. It therefore appears that this compound is particularly useful to prevent recurrent respiratory infections in children.
Bonfils
P
P
Laboratoire de Neurophysiologie, Collège de France, Paris.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000293:Adolescent; D001426:Bacterial Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006801:Humans; D007223:Infant; D012008:Recurrence; D012141:Respiratory Tract Infections / Q000517:prevention & control*
D000276:Adjuvants, Immunologic; D001426:Bacterial Proteins; C037567:glycoprotein, Klebsiella pneumoniae
Prophylaxie des infections des voies respiratoires chez l'enfant par le RU 41740.